Coronavirus Pandemic Effects On Incentive Compensation

White Paper

Coronavirus Pandemic Effects On Incentive Compensation

This paper focuses on coronavirus pandemic effects on IC for pharma companies in the short-term, medium-term, and long-term, while also providing prescriptive actions for sales exe ...

Patient-Centric Commercial Strategy

White Paper

Designing A Patient-Centric Commercial Strategy

This whitepaper addresses how RWE should be leveraged for informing various commercial decisions with a deeper-dive into marketing-mix analysis (MMx). ...

Corona Virus White Paper

White Paper

Can The Coronavirus Contagion Economically Infect The Global Pharmaceutical Industry?

Events surrounding the coronavirus contagion, characterized as a “black swan” event, which started in China, remain very fluid and are changing daily. No one really knows what ...

Importation of Drugs

White Paper

Importation Of Drugs Is Back Again On The Pharma Public Policy Table – A Short Commentary

This commentary white paper provides reasons why importation is still a bad idea today, but more importantly, why the reintroduction of this policy is a reflection of the broader e ...

AstraZeneca’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy

White Paper

AstraZeneca’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy

This paper explores the challenges and opportunities this new strategy can have for AstraZeneca while providing other pharma companies that are contemplating a similar different R& ...

US Recession Pharma Analytics

White Paper

How Will The Next Great Recession Affect The US Pharma Industry?

The US will have another recession as certain as night follows day. The business cycle has not been outlawed nor made extinct, contrary to the overly optimistic views of macroecono ...

Merger and Acquisitions

White Paper

Do Pharma Mergers And Acquisitions Improve R&D Productivity And Increase Shareholder Value?

Mergers & acquisitions (M&As) have long been used as a critical strategic instrument by pharmaceutical company executives to spur R&D innovation, sustain financial grow ...

Growing Attention Being Paid To Pharma Company Rebates And Discounts

White Paper

Growing Attention Being Paid To Pharma Company Rebates And Discounts

Pharma companies need to better understand how to manage rebates and discounts, while also developing a broader view of the effect on patients and the healthcare system. ...

Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US

White Paper

Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US

This white paper explores the unique challenges of ODs for RDs and the different approaches needed to address specific questions for their successful commercialization that vary fr ...

Perspectives On Pharma Company Use Of Open Payments Data

White Paper

Perspectives On Pharma Company Use Of Open Payments Data

This paper provides a detailed analysis on the role and effects of “Sunshine Laws” and payments made to providers as seen from published empirical evidence, intricacies and cha ...

How Regulatory Changes Are Driving The Future Of The Medical Device Industry

Report

How Regulatory Changes Are Driving The Future Of The Medical Device Industry

With new entrants from emerging countries giving the established brands a run for their money, the medical device market has become more competitive. ...

How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?

White Paper

How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?

The 2018 Congressional midterm elections are over after a bitter political fight. The voters have spoken. We are back to divided government, with Democrats controlling the House, a ...

Is The CVS-Aetna Merger A Pharma Industry Transformative Event?

White Paper

Is The CVS-Aetna Merger A Pharma Industry Transformative Event?

US antitrust officials recently approved the proposed $69 billion CVS-Aetna merger. This merger follows a similar action taken by the Justice Department to approve the Cigna-Expres ...

The Causes and Solutions of Chronic Drug Shortages in the United States

White Paper

The Causes and Solutions of Chronic Drug Shortages in the United States

While recent empirical research has exposed an array of causes for drug shortages, the application of better analytics has now also been cited as needed to account for these effect ...

Machine Learning and Data Mining in Pharmaceutical Commercial Analytics

White Paper

The Value of Machine Learning and Data Mining in Pharmaceutical Commercial Analytics

Increasing complexities of the pharma environment also mean that machine learning can provide earlier anticipation of and faster responses to new threats and opportunities. ...

The Reasons for and Solutions to Chronic Drug Shortages in the United States

White Paper

The Reasons for and Solutions to Chronic Drug Shortages in the United States

This white paper will briefly address the questions and present the key reasons for and solutions to the existence of chronic drug shortages in the US. It will also discuss the rol ...

Pricing and Market Effects of Biosimilar Entry in the US

White Paper

Pricing and Market Effects of Biosimilar Entry in the US

This white paper will provide insights into key questions as they pertain to the entry of biosimilars in the US market, pricing and market effects and the future of biosimilars in ...

Make US Pharma Great Again!? - Part 1

White Paper

Global Pharma Pricing and Market Effects of President Trump’s Proposed Policies

President Trump campaigned to use the buying power of the federal government to directly negotiate downward the prices of drugs used by Medicare patients. The question this white p ...

Implications From HEOR And RWE Models For Biopharmaceutical Commercial Analytics

Blog

Implications From HEOR And RWE Models For Biopharmaceutical Commercial Analytics

The following blog is an expanded summary of proposed research accepted for delivery at the upcoming 22nd ISPOR Annual International Meeting, Research Poster Presentations – ...

Make US Pharma Great Again!? - Part 1

White Paper

Make US Pharma Great Again!? – Part 2

Recent quotes from pharma CEOs about the effects of President Trump’s potential policy actions clearly point to added elements of risk and uncertainty for the industry.This comes ...

Make US Pharma Great Again!? - Part 1

White Paper

Make US Pharma Great Again!? – Part 1

The surprise election of Donald Trump as President of the United States has thrown greater uncertainty into many industries and individual companies on the receiving end of his ver ...

Econometric Analysis Of Biopharmaceutical Transfer Pricing

White Paper

Econometric Analysis Of Biopharmaceutical Transfer Pricing

The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of ...

Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far?

White Paper

Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far?

The question this commentary asks is simply this – has the pendulum swung too far in the direction of excessive restrictions on sales and marketing practices of biopharmaceut ...

Patient Claims Versus EHR Data – How To Choose Between The Two?

White Paper

Patient Claims Versus EHR Data – How To Choose Between The Two?

The topics this white paper will review are which dataset is more appropriate for answering certain types of business questions, look at some cases from the academic literature tha ...

Is Biopharmaceutical Industry Drug Demand Becoming More Recession Sensitive?

White Paper

Is Biopharmaceutical Industry Drug Demand Becoming More Recession Sensitive?

The Great Recession in the U.S. not only marked a period of the longest and by many measures the largest economic downturn since The Great Depression of the 1930’s, but also alte ...

The Relationship Between Drug Price Controls And Patient Health Outcomes

White Paper

The Relationship Between Drug Price Controls And Patient Health Outcomes

No long-term “solution” on drug pricing has emerged gaining broad consensus among public policy officials and politicians, patient advocacy groups, medical and health service r ...

The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment

White Paper

The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment

The growing shift to specialty medicines in the US pharma market is well documented. Pricing issues are becoming more common and controversial, with questions being raised about th ...

Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics

White Paper

Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics

The latest pharma R&D cost estimates illustrate that greater pressures will increasingly be placed on companies to find greater cost efficiencies, reduce risks, improve pipelin ...

White Paper

Deploying K-Nearest Neighbor Modeling Methodologies For Real World Problems

There has been an immense improvement of theory and algorithms in recent times leading to enhancement in computation power. Also, online data availability was never easier than now ...